Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials
- 36 Downloads
To assess whether an adjunctive therapy of Sodium Tanshinone II A Sulfonate Injection (STS) is effective and safe in improving clinical outcomes in patients with coronary heart disease (CHD).
literature search was conducted through PubMed, the Cochrane Library, Knowledge Infrastructure Databases (CNKI), Chinese Biomedical Literature Database (SinoMed), Chinese Science and Technology Periodical Database (VIP) and Wanfang Database up to August 2017. Randomized controlled trials (RCTs) comparing STS with placebo or no additional treatments on the basis of standard conventional medicine therapies were included. The outcomes were all-cause mortality, major acute cardiovascular events (MACEs), cardiac function and inflfl ammatory factors. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses.
A total of 22 RCTs involving 1,873 participants were included. All of the trials used STS as adjunctive treatment to standard conventional medicine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of STS with percutaneous coronary intervention (PCI) or thrombolytic therapy (TT) might be more effective on reduction of all cause death rate than TT alone [risk ratio (RR) 0.25, 95% confifi dence interval (CI) 0.07 to 0.87] or PCI alone (RR 0.42, 95% CI 0.04 to 4.36). The results of 6 trials comparing STS plus TT with TT alone showed that the addition of STS signififi cantly reduced the incidence of cardiac shock (RR 0.35, 95% CI 0.14 to 0.86), heart failure (RR 0.41, 95% CI 0.20 to 0.83) and arrhythmia (RR 0.21, 95% CI 0.12 to 0.46). STS combined with TT also showed a superior effect on cardiac function and inflammatory factor. No severe adverse event was reported related to STS.
As an adjunctive therapy, STS combined with standard conventional medicine seems to be more effective on all-cause mortality or MACEs than conventional medicine treatment alone with less side effects. However, we cannot make a fifi rm conclusion due to low quality of inclusion trials. Well-designed trials with high methodological quality are needed to validate the effect of STS for CHD patients.
KeywordsTanshinone II A coronary heart disease meta-analysis systematic review
Unable to display preview. Download preview PDF.
- 8.Wang MZ, Yan FS, Gao FY. Analysis of high performance liquid chromatography on three tanshinones from Salviamilt iorrhizae. J Pharm Ana lysis 1985;5:348–350.Google Scholar
- 10.Chen Z, Xu H. Anti-inflammatory and immunomodulatory mechanism of tanshinone II A for atherosclerosis. Evid Based Complement Alternat Med 2014:2014:267976.Google Scholar
- 11.Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 ed. The Cochrane Collaboration 2009.Google Scholar
- 12.Du QM, Wang CX. Effects of sodium tanshinone II A sulfonate on arrhythmia induced by myocardial ischemiareperfusion. Chin J Geriatric Heart Brain Vessel Dis (Chin) 2011;13:349–351.Google Scholar
- 13.Fan LY, Yang J. Impact of tanshinone II A sulfonic acid natrium on blood lipid metabolism, serum inflammatory cytokines levels and cardiac function in patients with acute myocardial infarction. Pract J Cardiac Cerebral Pneumal Vascular Dis (Chin) 2015;23:14–17.Google Scholar
- 14.Gan SY, Rong RC, Li B. Effects tanshinone II A on infl ammatory cytokines and oxidative stress of the patient with acute coronary syndrome. Pharm Clin Chin Materia Medica (Chin) 2014; 30:163–166.Google Scholar
- 15.He Y. Efficacy and safety of Danshen Injection in treating patients with unstable angina pectoris of qi defi ciency and blood stasis type in perioperative period of interventional therapy: a clinical study of the efficacy and safety of II A [Dissertation]. Urumqi: Xinjiang Medical University; 2016.Google Scholar
- 16.Huang PH. Protection of sodium tanshinone II A sulfonate on myocardium reperfusion injury after AMI thrombolysis. Med Frontier (Chin) 2012;20:350–351.Google Scholar
- 17.Li CR, Gan SY, Huang HX. Study on the curative effect of sodium tanshinone II A sulfonate in patient with acute coronary syndrome and its infl uence on infl ammatory cytokines. Modern J Integr Tradit Chin West Med (Chin) 2015;24:2284–2286.Google Scholar
- 18.Li JC, Sun ZG. Influence of Tanshinone II A Sulfonate Injection combined with simvastatin on infl ammatory factor in patients with coronary heart disease. Chin Primary Health Care (Chin) 2015;29:111–112.Google Scholar
- 19.Li RJ, Zhang KS. Infl uence of Tanshinone II A Sulfonate Sodium Injection on latelet activation in patients with unstable angina pectoris of coronary atherosclerotic heart disease with blood stasis syndrome. China Pharmaceuticals (Chin) 2017;29:63–65.Google Scholar
- 21.Li Y. Effect of tanshinone II A on the cardiac function and inflammatory cytokines in patients with acute myocardial infarction. J Hainan Med Univ (Chin) 2016;22:1933–1935.Google Scholar
- 22.Liu PF, Zhang YM, Tang JW, Li HL. The effect and clinical signifi cance of Tanshinone Injection on plasma NT-proBNP in acute myocardial infarction. Chin J Diffi cult Complicated Cases (Chin) 2009;8:327–329.Google Scholar
- 23.Luan T, Pan T. Effects of Tanshinone Injection on myocardial ischemia reperfusion injury and different syndromes of TCM. Chin J Integr Med Cardio-/Cerebrovas Dis (Chin) 2012;10:524–526.Google Scholar
- 24.Qi H, Zhao X, Li YF. Study on the curative effect of Sodium Tanshinone II A Sulfonate Injection in treating acute myocadiac infarction. China Med Herald (Chin) 2006;3:22–23.Google Scholar
- 25.Qin S. C1inical efficacy of tanshinone plus atorvastatin against CHD. Clin J Chin Med (Chin) 2012;4:25–27.Google Scholar
- 26.Tang XJ. Clinical study of coronary heart disease and angina pectoris with blood stasis syndrome treated by Sodium Tanshinone II A Sulfonate Injection [Dissertation]. Beijing: Beijing University of Chinese Medicine; 2014.Google Scholar
- 27.Wei Q, Shen XJ. Effects of tanshinone II on clinical symptoms and vascular aging factor in angina pectoris of coronary heart disease patients. J Basic Chin Med (Chin) 2014;20:783–785.Google Scholar
- 28.Xie Q, Zhang XJ. 31 cases of clinical observation research of Sodium Tanshinone II A Sulfonate Injection in patients with angina after infarction. Chin J Ethnomed Ethnopharm (Chin) 2016;25:126–128.Google Scholar
- 29.Xu T, Zhang Z, Wang JP, Feng FY, Liu X. Effect of sodium tanshinone II A sulfonate combined with atorvastatin on TL R4 inflammatory signal pathway and immune function of patients with coronary heart diseases. Hebei Med J (Chin) 2015;37:3365–3368.Google Scholar
- 30.Zhang XR, Wang LJ, Liu HJ, Dong W, Guo YB. The impact of Tan treatment on haemodynamics and blood lipid of acute myocardial infarction patients. J Guizhou Med Univ (Chin) 2014;39:379–382.Google Scholar
- 31.Chang JY, Wang SZ, and Yan JX. Impact of tanshinone II A on cardiac function and hs-CRP, TNF-α, IL-6 Levels of patients with acute myocardial infarction. China Med Pharm (Chin) 2016;6:142–145.Google Scholar
- 32.Chen J. Influence of Sodium Tanshinone II A Sulfonate Injection in thrombolytic therapy of acute myocardial infarction patients. Tianjin Pharm (Chin) 2007;19:35–36.Google Scholar
- 33.Chu C, Tao ZG, Fan YJ. Effect of Sodium Tanshinone II A Sulfonate Injection on the serum infl ammatory factors in acute coronary syndrome. Shandong Med J (Chin) 2014;54:67–68.Google Scholar
- 34.Yan GP, Zhu CL, Sun YQ. Meta-analysis of Salvianolate Injection in the treatment of unstable angina pectoris. J Emerg Trad Chin Med 2015;5:771–774.Google Scholar
- 37.Wang X. Progress of pharmacological research and clinical application of tanshinone II A," Guangming J Chin Med (Chin) 2011;26:1514–1517.Google Scholar
- 38.Bai FM. Clinical application progress of sodium tanshinone II—a sulfonate. China Pharm (Chin) 2012;23:1770–1772.Google Scholar
- 39.Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018;391:319–328.CrossRefPubMedGoogle Scholar